Duopharma Biotech sees profit growth in Q1 FY2026 alongside insulin supply normalisation

May 15, 2026 -- Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) recorded resilient financial performance in the first quarter ended 31 March 2026, delivering a stronger Profit Before Tax (“PBT”) of RM 40.41 million, and Profit After Tax (“PAT”) of RM30.71 million, increasing 19.8% year-on-year, despite Q1FY2026 revenue of RM247.88 million dropping 5.7% compared to RM262.74 million in the same period last year. The moderation in revenue was primarily attributable to public sector demand for insulin products, which has normalised to regular supply levels following the one-off surge in sales experienced in Q1 FY2025.

The Group’s revenue performance was supported by growth in the private and export segments, which delivered encouraging year-on-year growth during the quarter, driven in part by the strong performance of the Consumer Healthcare business. A stronger Ringgit in the quarter also eased Active Pharmaceutical Ingredient (“API”) input costs, combining with lower operating expenses and reduced net finance costs to achieve higher PBT for the period.

Meanwhile, Q1FY 2026 revenue was 10.3% higher compared to Q4 FY2025, supported by positive growth across all business segments, driven by public sector demand in line with the Government’s annual procurement cycle. Quarter-on-quarter PBT grew 62.2% and PAT grew 61.2% respectively, underpinned by a higher revenue base and improved operational efficiency.

Duopharma Biotech Group Chief Executive Officer Wan Amir-Jeffery bin Wan Abdul Majid commented, “The Government’s strategic commitment to healthcare and medicine supply security augurs well for the Group. We anticipate a favourable operating environment in light of the deliberate emphasis on expanding local pharmaceutical manufacturing capabilities, as indicated in the 13th Malaysia Plan (“RMK-13”) and the New Industrial Master Plan 2030 (“NIMP 2030”). As a leading homegrown pharmaceutical manufacturer in Malaysia, Duopharma Biotech is uniquely positioned to capitalise on these structural opportunities. At the same time, to safeguard continuity of production during global macroeconomic and geopolitical volatility, we have proactively strengthened our supply chain resilience through strategic inventory management, diversification of API sourcing and close engagement with key suppliers.”

The Company was recently awarded two Government insulin contracts via wholly-owned subsidiaries. In February 2026, the Government accepted the tender offer from Duopharma

(M) Sendirian Berhad (“DMSB”) to supply Insulin Injection to Ministry of Health facilities for a period of two (2) years until 5 February 2028, with a total contract value of RM52.54 million. The Government also accepted the tender offer from Duopharma Marketing Sdn Bhd (“DMktg”), together with Biocon Sdn Bhd (“Biocon”), to supply Recombinant Human Insulin Formulations (“RHI”) to Ministry of Health facilities until 15 May 2026, with a total contract value of RM65.08 million. The Company is also contracted to supply a total of 100 products to Ministry of Health facilities until 31 December 2026.

During Q1 FY2026, the Group paid a second interim dividend of 3.05 sen per share (payout in Q1 FY2025: 2.0 sen per share) equivalent to RM29.33 million (value in Q1 FY2025: RM19.24 million) in respect of financial year ended 31 December 2025.

Dear Valued Shareholders,

Duopharma Biotech Berhad (“the Company”) is pleased to inform you that the Company has issued the following documents/ reports:-

(1) Notification to Shareholders

(2) Notice of the 25th Annual General Meeting (“AGM”), Proxy Form and Administrative Guide

(3) Integrated Annual Report (“IAR”) 2025

(4) Corporate Governance Report (“CG Report”) 2025; and

(5) Sustainability Report (“SR”) 2025.

The Notification to Shareholders, Notice of the 25th AGM, Proxy Form, Administrative Guide, IAR 2025, and CG Report 2025 are available in the ‘Investor Relations’ section, and the SR 2025 is available in the ‘Environmental, Social and Governance’ section on our website. The aforesaid documents/reports are also available via the announcement made on the website of Bursa Malaysia Securities Berhad.

Thank you.

Release ID: 89191866